# Special Issue

## New Potent Antibacterial Agents

### Message from the Guest Editor

Bacteria have developed several mechanisms to circumvent antibiotic activity, causing therapeutic failures. Faced with the worldwide problem of antibiotic resistance, there is an urgent need to discover and develop new antibacterial agents. In this Special Issue, new potent antibacterial agents with mechanical and structural varieties will be considered as therapeutic approaches to defeat both Gram-positive and Gram-negative pathogens. We will cover the development of new antibiotics resulting from research on medicinal chemistry and synthetic biology, bioactive agents such as bacteriophages and bacteriocins, antibiotic interactions, and adjuvants that target the bacterial lifecycle (such as virulence and communication) or drug resistance mechanisms (such as antibiotic efflux and permeation). All types of articles falling within the scope of the above research areas are welcome.

### Guest Editor

Prof. Dr. Muriel Masi

1. MCT, INSERM U1261, UMR_MD1, Aix-Marseille University & IRBA SSA, 27 Boulevard Jean Moulin, 13005 Marseille, France
2. Synchrotron SOLEIL, L'Orme des Merisiers, Départementale 128, 91190 Saint-Aubin, France

### Deadline for manuscript submissions

closed (30 July 2021)

**Antibiotics**

**an Open Access Journal by MDPI**

**Impact Factor 4.6**
**CiteScore 8.7**
**Indexed in PubMed**

mdpi.com/si/73079

*Antibiotics*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

# Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

### Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

### Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )

MDPI